J&J(US:JNJ) Prnewswire·2026-01-10 15:00Core Insights - Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-1 study of amivantamab combined with chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer, showing over 70% response rates in the first-line subgroup and durable responses lasting beyond 16 months [1][2][5] Study Results - The study demonstrated a confirmed overall response rate (ORR) of 51% across all patients, with a median duration of response (DOR) of 9.3 months and a median progression-free survival (PFS) of 9.2 months [5][6] - In the first-line subgroup, the ORR was 73%, with some patients maintaining responses for over two years, and four patients proceeding to curative intent surgery [5][6] - Notable activity was observed in patients with liver metastases, achieving an ORR of 57% and a median PFS of 11.3 months [6] Safety Profile - The safety profile of amivantamab plus chemotherapy was consistent with previous reports, with treatment-related adverse events primarily linked to EGFR and MET inhibition [6] - Only 9% of patients discontinued therapy due to treatment-related adverse events, with neutropenia being the most common Grade 3 or higher event [6] Future Directions - Johnson & Johnson is advancing pivotal Phase 3 studies (OrigAMI-2 and OrigAMI-3) to further evaluate amivantamab-based regimens in both first- and second-line colorectal cancer settings [7]